Tillkännagivande • Apr 10
Sinopharm Group Co. Ltd. to Report Q1, 2026 Results on Apr 24, 2026 Sinopharm Group Co. Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026 Tillkännagivande • Mar 23
Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026 Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026. Tillkännagivande • Mar 10
Sinopharm Group Co. Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026 Sinopharm Group Co. Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026 Tillkännagivande • Nov 28
Sinopharm Group Co. Ltd. Announces Board and Committee Resignations The board of directors of Sinopharm Group Co. Ltd. announced that on 28 November 2025, due to the work arrangement, Mr. Zhao Bingxiang ("Mr. Zhao") tendered his resignation to the Board as a non-executive Director, the chairman (the "Chairman") of the Board, the chairman of the nomination committee of the Board (the "Nomination Committee"), the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee"), a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee") and the authorized representative (the "Authorized Representative") of
the Company (pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")), and Ms. Feng Rongli ("Ms. Feng") tendered her resignation to the Board as a non-executive Director, a member of the remuneration committee of the Board and a member of the Nomination Committee. Each of the above resignations shall take effect from the appointment of their respective replacement at the general meeting of the Company. Tillkännagivande • Oct 10
Sinopharm Group Co. Ltd. to Report Nine Months, 2025 Results on Oct 24, 2025 Sinopharm Group Co. Ltd. announced that they will report nine months, 2025 results on Oct 24, 2025 Tillkännagivande • Aug 12
Sinopharm Group Co. Ltd. to Report First Half, 2025 Results on Aug 22, 2025 Sinopharm Group Co. Ltd. announced that they will report first half, 2025 results on Aug 22, 2025 Tillkännagivande • Apr 10
Sinopharm Group Co. Ltd. to Report Q1, 2025 Results on Apr 25, 2025 Sinopharm Group Co. Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025 Tillkännagivande • Mar 12
Sinopharm Group Co. Ltd. to Report Fiscal Year 2024 Results on Mar 21, 2025 Sinopharm Group Co. Ltd. announced that they will report fiscal year 2024 results on Mar 21, 2025 Tillkännagivande • Feb 12
Sinopharm Group Co. Ltd. Approves Board Appointments Sinopharm Group Co. Ltd. announced at its EGM held on February 12, 2025, the shareholders approved appointment of Mr. Sun Jinglin as an executive Director of the sixth session of the Board; Mr. Hu Ligang as a non-executive Director of the sixth session of the Board; Mr. Zu Jing as a non-executive Director of the sixth session of the Board; and Mr. Xing Yonggang as a non-executive Director of the sixth session of the Board. Tillkännagivande • Jan 08
Sinopharm Group Co. Ltd. Announces Board Resignations Sinopharm Group Co. Ltd. announced that, due to work needs, Mr. Wang Kan and Mr. Wang Peng have tendered their resignation as non-executive directors to the board on 8 January 2025. The resignations will take immediate effect. Tillkännagivande • Oct 14
Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024 Sinopharm Group Co. Ltd. announced that they will report nine months, 2024 results on Oct 25, 2024 Tillkännagivande • Aug 28
Sinopharm Group Co. Ltd. Announces Change in President The Board of Sinopharm Group Co. Ltd. announced that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. Mr. Liu Yong ("Mr. Liu") ceased to be the President. The above arrangements took effect immediately. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024. Tillkännagivande • Aug 27
Sinopharm Group Co. Ltd. Announces Management Changes The board of directors of Sinopharm Group Co. Ltd. announced that it resolved to propose to appoint Mr. Zhao Bingxiang ("Mr. Zhao") as the non-executive Director and Mr. Lian Wanyong ("Mr. Lian") as the executive Director
(the "Proposed Appointment of Directors") on 27 August 2024. In accordance with the articles of association of the Company (the "Articles of Association"), the above Proposed Appointment of Directors are subject to the approval by the shareholders of the Company (the "Shareholders") at the extraordinary general meeting of the Company. The Board hereby announces that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. The Board hereby announces that on 27 August 2024, due to work needs, Mr. Yu Qingming ("Mr. Yu") ceased to be the Chairman of the Board, an executive Director as well as the chairman of the Nomination Committee, the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee") and a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee"); Mr. Liu Yong ("Mr. Liu") ceased to be an executive Director, the President and a member of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee. The
above arrangements took effect immediately. China National Pharmaceutical Group Co. Ltd. will make other appointments for Mr. Yu and Mr. Liu. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets
management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024. Tillkännagivande • Aug 09
Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Sinopharm Group Co. Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Tillkännagivande • Jun 14
Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024 Sinopharm Group Co. Ltd. declared final dividend of RMB 0.87 per share for the fiscal year ended December 31, 2023. Ex-dividend date is 17 June 2024. Record date is 24 June 2024Payment date is 13 August 2024. Tillkännagivande • Apr 17
Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Sinopharm Group Co. Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Tillkännagivande • Mar 13
Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024 Sinopharm Group Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024 Tillkännagivande • Oct 14
Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023 Sinopharm Group Co. Ltd. announced that they will report nine months, 2023 results on Oct 27, 2023 Tillkännagivande • Sep 16
Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief Supervisor Sinopharm Group Co. Ltd. at its EGM held on September 15, 2023, considered and approved (if thought fit) the appointment of Mr. Guo Jinhong as a shareholder representative Supervisor of the sixth session of the Supervisory Committee, to authorize the Supervisory Committee to determine his remuneration and to authorize the chairman of the Board or any executive Director to enter into the service contract or such other documents or supplemental agreements or deeds with him. The Board also announced that the sixth session of the Supervisory Committee comprises five Supervisors, and the independent Supervisors are Ms. Guan Xiaohui and Mr. Liu Zhengdong, shareholderrepresentative Supervisor is Mr. Guo Jinhong and the employee representative Supervisors are Mr. Liu Hongbing and Ms. Lu Haiqing. The first meeting of the sixth session of the Supervisory Committee was held on 15 September 2023 and resolved to elect Ms. Guan Xiaohui as the chief Supervisor of the Supervisory Committee. Tillkännagivande • Aug 29
Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive Director Sinopharm Group Co. Ltd. announced meanwhile, in view of the retirement of Mr. Ma Ping, a non-executive Director, the Board resolved at the same meeting to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Mr. Ma Ping, a non-executive Director of the fifth session of the Board, will retire upon the approval of appointment of Directors of the sixth session of the Board at the extraordinary general meeting of the Company. Mr. Ma Ping has confirmed that he has no disagreement with the Board, and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders (the "Shareholders") and creditors of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma Ping for his contributions to the Company during his tenure as a Director. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Tillkännagivande • Aug 16
Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023 Sinopharm Group Co. Ltd. announced that they will report first half, 2023 results on Aug 25, 2023 Tillkännagivande • May 19
Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive Director Sinopharm Group Co. Ltd. (the Company) announced that on 18 May 2023, due to attainment of the term of service of independent non-executive Directors as stipulated in the Rules of Procedure of Board of Directors of the Company, Mr. Zhuo Fumin (Mr. Zhuo) tendered his resignation as an independent non-executive Director of the Company, a member of the audit committee of the Board (the Audit Committee), and a member of the nomination committee of the Board (the Nomination Committee), which shall take effect from the appointment of his replacement at the general meeting of the Company. Mr. Zhuo has confirmed that he has no disagreement with the Board and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders of the Company (the Shareholders) and creditors of the Company. 